UK Pharmaceuticals Export Market

UK Pharmaceuticals Export Market Overview:

The UK pharmaceuticals export market size reached USD 26.98 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 42.58 Billion by 2032, exhibiting a growth rate (CAGR) of 4.80% during 2024-2032. Strong research and development (R&D) capabilities, rising innovative drug development, advanced manufacturing infrastructure, a skilled workforce, favorable UK's regulatory framework, international partnerships, access to global markets, and the growing demand for specialty drugs and biopharmaceuticals are some of the major factors driving the growth of the market.

UK Pharmaceuticals Export Market Trends:

Strong Research and Development (R&D) and Innovation

The UK's advanced research and development capabilities, particularly in biotechnology and life sciences, lead to the creation of innovative drugs. For instance, in May 2024, The Industrial Biotechnology Innovation Catalyst (IBIC), launched by The University of Manchester established the north-west of England as a global leader in biotechnology innovation, boosting job creation, collaboration, investment, and upskilling in the region. The project leverages a £5 million investment from the EPSRC’s Place-Based Impact Acceleration Account to stimulate innovation and commercial growth. The IBIC will give businesses and start-ups a platform to engage with higher education institutions, governmental organizations, and researchers in the north-west, and support translating fundamental biotechnology research from the lab to the real world. The IBIC launches at a significant time for the UK’s biotechnology market. The UK Government’s focus on biotechnology and the new £5 million sandbox fund signal increasing interest in the sector, which was valued at £21.8billion in 2023.

Global Market Access

Favorable trade agreements and international partnerships enable the UK to export pharmaceuticals to a wide range of markets efficiently. For instance, in September 2024, Owen Mumford, a company in the design, manufacture, and advancement of medical devices, renewed its long-standing logistics partnership with Davies Turner for an additional three-year term. The renewed contract, which emphasizes a long-term commitment, will continue to see Davies Turner providing comprehensive UK logistics solutions, EU exports, and NHS fulfilment services for Owen Mumford. This collaboration is pivotal in ensuring the seamless distribution of Owen Mumford's medical devices, including its pharmaceutical solutions, across the UK and Europe. Similarly, according to IBEF, India aims to achieve US$ 31 billion in pharmaceutical exports in FY25, with the United Kingdom (UK) and the United States (US) identified as primary markets. In FY24, pharmaceutical exports from India totaled US$ 27.9 billion, reflecting a 9.6% growth as compared to the previous year. The Pharmaceutical Exports Promotion Council (Pharmexcil) revealed that it aims to target US$ 1 billion in exports to the UK, citing the rising demand for affordable generics in the country. Pharmexcil intends to conduct a roadshow in Belgium, the Netherlands, and the UK in November to further bolster exports.

UK Pharmaceuticals Export Market News:

• In April 2024, UK Export Finance (UKEF) and Barclays secured a £1.3 million trade finance package for Leicester-based business Unimed Procurement Services. The financing has allowed Unimed to fulfil a major delivery of over 350 ultrasound machines to Latin America and expand its international reach. Unimed supplies governments, NGOs, research institutions and hospitals with medical equipment, pharmaceuticals, and medicine.

UK Pharmaceuticals Export Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product type, therapeutic application, and distribution channel.

Product Type Insights:

• Branded Pharmaceuticals
• Generic Pharmaceuticals
• OTC (Over-the-Counter) Drugs
• Biopharmaceuticals
• Active Pharmaceutical Ingredients (APIs)
• Vaccines
   

The report has provided a detailed breakup and analysis of the market based on the product type. This includes branded pharmaceuticals, generic pharmaceuticals, OTC (over-the-counter) drugs, biopharmaceuticals, active pharmaceutical ingredients (APIS) and vaccines.

Therapeutic Application Insights:

• Cardiovascular
• Oncology
• Central Nervous System (CNS)
• Infectious Diseases
• Respiratory
• Endocrinology
• Dermatology
• Gastroenterology
• Others
   

A detailed breakup and analysis of the market based on the therapeutic application have also been provided in the report. This includes cardiovascular, oncology, central nervous system (CNS), infectious diseases, respiratory, endocrinology, dermatology, gastroenterology, and others.

Distribution Channel Insights:

• Direct Exports
• Contract Manufacturing
• Online Pharmacies
• Others
   

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes direct exports, contract manufacturing, online pharmacies, and others.

Regional Insights:

• London
• South East
• North West
• East of England
• South West
• Scotland
• West Midlands
• Yorkshire and The Humber
• East Midlands
• Others
   

The report has also provided a comprehensive analysis of all the major regional markets, which include London, South East, North West, East of England, South West, Scotland, West Midlands, Yorkshire and The Humber, East Midlands, and Others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

UK Pharmaceuticals Export Market Report Coverage:

Key Questions Answered in This Report:

• How has the UK pharmaceuticals export market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the UK pharmaceuticals export market?
• What is the breakup of the UK pharmaceuticals export market on the basis of product type?
• What is the breakup of the UK pharmaceuticals export market on the basis of therapeutic application?
• What is the breakup of the UK pharmaceuticals export market on the basis of distribution channel?
• What are the various stages in the value chain of the UK pharmaceuticals export market? 
• What are the key driving factors and challenges in the UK pharmaceuticals export?
• What is the structure of the UK pharmaceuticals export market and who are the key players?
• What is the degree of competition in the UK pharmaceuticals export market?  

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the UK pharmaceuticals export market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the UK pharmaceuticals export market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the UK pharmaceuticals export industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.